Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.430
+0.060 (1.78%)
Aug 15, 2025, 10:01 AM - Market open

Arbutus Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-54.25-69.92-72.85-69.46-76.25-63.75
Upgrade
Depreciation & Amortization
1.011.381.41.431.751.98
Upgrade
Loss (Gain) From Sale of Assets
---0.02---
Upgrade
Asset Writedown & Restructuring Costs
2.980.17----
Upgrade
Loss (Gain) From Sale of Investments
-3.29-3.14-2.2-0.0510.21
Upgrade
Loss (Gain) on Equity Investments
-----2.55
Upgrade
Stock-Based Compensation
8.228.999.37.186.426.16
Upgrade
Other Operating Activities
0.840.5-3.34-3.7-1.390.98
Upgrade
Change in Accounts Receivable
0.74-0.63-0.42-0.450.41-0.11
Upgrade
Change in Accounts Payable
-6.6-2.71-5.765.221.911.67
Upgrade
Change in Unearned Revenue
-11.03-1.36-10.6622.46--
Upgrade
Change in Other Net Operating Assets
1.191.87-1.392.03-1.4-1.13
Upgrade
Operating Cash Flow
-60.19-64.85-85.94-35.36-67.53-51.44
Upgrade
Capital Expenditures
-0.09-0.18-1.01-0.51-0.81-0.23
Upgrade
Sale of Property, Plant & Equipment
0.01-0.02---
Upgrade
Investment in Securities
28.4623.1351.76-74.43-11.87-14.68
Upgrade
Investing Cash Flow
28.3922.9550.77-74.94-12.68-14.91
Upgrade
Issuance of Common Stock
6.435230.6531.81137.2486.75
Upgrade
Financing Cash Flow
6.435230.6531.81137.2486.75
Upgrade
Foreign Exchange Rate Adjustments
-0-0.050.03-0.020.010.06
Upgrade
Net Cash Flow
-25.3810.05-4.49-78.5157.0320.45
Upgrade
Free Cash Flow
-60.28-65.03-86.94-35.87-68.34-51.67
Upgrade
Free Cash Flow Margin
-391.00%-1053.83%-479.27%-91.92%-621.96%-747.32%
Upgrade
Free Cash Flow Per Share
-0.32-0.35-0.52-0.24-0.64-0.68
Upgrade
Levered Free Cash Flow
-35.02-41.56-51.58-9.73-38.42-30.17
Upgrade
Unlevered Free Cash Flow
-34.95-41.47-51.3-8.65-36.63-27.66
Upgrade
Change in Working Capital
-15.7-2.83-18.2329.240.930.43
Upgrade
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q